Highlights
- GLP-1 receptor agonists (GLP-1 RAs) are associated with a 35% reduction in myocardial infarction and a 22% reduction in ischemic stroke in T2D patients with retinopathy.
- Ocular protection: The use of GLP-1 RAs reduced the risk of progression to proliferative diabetic retinopathy (PDR) by 22% and retinal vein occlusions (RVO) by 30%.
- Renal benefits were profound, with a 60% reduction in the need for renal replacement therapy (RRT).
- The data suggest GLP-1 RAs do not increase the risk of NAION or retinal artery occlusions, addressing long-standing clinical concerns.
Background
Type 2 diabetes (T2D) remains a primary driver of global morbidity and mortality, often complicated by a cluster of microvascular and macrovascular pathologies. Diabetic retinopathy (DR) is not only a leading cause of vision loss but also serves as a critical clinical marker for systemic vascular vulnerability. Historically, patients with advanced DR were often excluded from large-scale cardiovascular outcome trials (CVOTs). Furthermore, early data from the SUSTAIN-6 trial raised concerns regarding the “early worsening” of retinopathy following rapid glycemic improvement with semaglutide.
As the prevalence of diabetes continues to impact life expectancy—contributing to a net loss of 0.09 years in life expectancy in certain populations since 1990—and as multimorbidity becomes the norm rather than the exception, identifying therapies that offer multi-organ protection is paramount. This review synthesizes recent evidence on the efficacy of GLP-1 receptor agonists (GLP-1 RAs) in a high-risk population: those with both T2D and pre-existing DR.
Key Content
Macrovascular Protection in Patients with Retinopathy
The study by Shah et al. (2026), utilizing the TriNetX research network, evaluated 173,216 adults with T2D and DR. Following propensity score matching (PSM), the cohort of 30,613 individuals receiving GLP-1 RAs (including semaglutide, dulaglutide, and tirzepatide) showed substantial macrovascular benefits over a two-year period.
Patients on GLP-1 RAs experienced a significantly decreased risk of:
- Myocardial Infarction (MI): HR 0.65; 95% CI, 0.61-0.69
- Ischemic Stroke: HR 0.78; 95% CI, 0.74-0.83
- Coronary Revascularization: HR 0.75; 95% CI, 0.67-0.84
- Heart Failure Exacerbation: HR 0.78; 95% CI, 0.76-0.81
These findings reinforce the systemic cardioprotective effects of this class, even in patients whose microvascular status (the presence of DR) indicates advanced disease progression.
Ocular Microvascular Outcomes
One of the most significant contributions of recent research is the clarification of GLP-1 RAs’ impact on the retina. In the Shah et al. study, GLP-1 RA use was associated with a reduced risk of progressing to proliferative diabetic retinopathy (PDR) (HR 0.78; 95% CI, 0.71-0.86). Additionally, the risk of developing neovascular glaucoma—a devastating complication of ischemic DR—was reduced (HR 0.65; 95% CI, 0.47-0.89).
Notably, the study observed a 30% reduction in Retinal Vein Occlusions (RVOs), suggesting that the anti-inflammatory and endothelial-stabilizing properties of GLP-1 RAs may extend to the retinal vasculature. Crucially, there was no statistically significant association between GLP-1 RA use and Non-Arteritic Ischemic Optic Neuropathy (NAION) (HR 0.88; 95% CI, 0.54-1.44) or Retinal Artery Occlusions (RAO), providing much-needed safety reassurance for clinicians.
Renal and Peripheral Vascular Integrity
The interplay between the eye and the kidney in diabetes is well-documented; patients with severe retinopathy often exhibit concurrent nephropathy. The Shah et al. cohort demonstrated that GLP-1 RAs significantly mitigated renal decline:
- Acute Kidney Injury (AKI): HR 0.68; 95% CI, 0.66-0.71
- Renal Replacement Therapy (RRT): HR 0.40; 95% CI, 0.36-0.43
Furthermore, lower extremity amputations, a surrogate for severe peripheral arterial disease and neuropathy, were reduced by 22% (HR 0.78; 95% CI, 0.69-0.88).
Contextual Risk Factors: Visceral Fat and Multimorbidity
Recent prospective cohort studies, such as the China Metabolic Management Center (MMC) project, have highlighted that Visceral Fat Area (VFA) is a significant independent risk factor for diabetic kidney disease (DKD), showing a U-shaped relationship in men and a linear risk increase in women. This underscores the importance of the weight-loss benefits associated with GLP-1 RAs, which may indirectly contribute to the observed reduction in AKI and RRT by addressing visceral adiposity.
Additionally, population-level data from England suggest that diabetes is among the top four conditions leading to the acquisition of multiple long-term conditions (MLTCs). The ability of GLP-1 RAs to provide multi-systemic protection is therefore vital in slowing the “multimorbidity progression rate,” which increases significantly after the acquisition of the second chronic condition.
Expert Commentary
The findings from this real-world evidence study (Shah et al., 2026) are transformative. For years, the “early worsening” phenomenon observed in SUSTAIN-6 led to caution when prescribing GLP-1 RAs to patients with advanced DR. However, this larger cohort suggests that over a two-year horizon, the net effect on the eye is overwhelmingly positive.
Mechanistically, GLP-1 RAs likely provide protection through more than just glycemic control. Their effects on blood pressure reduction, weight loss (specifically visceral fat), and direct anti-inflammatory pathways in the endothelium are critical. The observation that NSTEMI (non-ST-elevation myocardial infarction) is more closely linked to complications like retinopathy and albuminuria than STEMI—as seen in the FinnDiane Study—highlights the complex interplay of multiple risk factors in patients with vascular damage. GLP-1 RAs appear to address this complexity by targeting shared pathways of atherosclerosis and microvascular rarefaction.
One limitation of current evidence remains the retrospective nature of database studies, which can be prone to selection bias, although PSM helps mitigate this. Future prospective trials, such as the ongoing FOCUS study, will provide more definitive longitudinal data on long-term retinal outcomes.
Conclusion
In patients with T2D and pre-existing diabetic retinopathy, GLP-1 RAs are associated with a substantial reduction in both systemic macrovascular events and severe ocular complications. The class not only protects the heart and kidneys but also reduces the risk of vision-threatening progression to PDR and RVO. Clinicians should feel increasingly confident in utilizing these agents to manage high-risk diabetic populations, recognizing their role as a comprehensive tool for vascular preservation.
References
- Shah J, et al. Glucagon-Like Peptide-1 Receptor Agonists and Risk of Systemic and Ocular Vascular Complications in Patients with Type 2 Diabetes and Diabetic Retinopathy. American journal of ophthalmology. 2026. PMID: 42025665.
- Zhang X, et al. Sex-specific and BMI-specific associations between visceral fat and diabetic kidney disease in patients with diabetes: a large-scale multicentre prospective cohort study. Lancet Diabetes Endocrinol. 2026. PMID: 41991218.
- Sankaranarayanan R, et al. Progression of multiple long-term conditions (multimorbidity) in England: a population-based descriptive study of 49·6 million adults. Lancet Public Health. 2026. PMID: 42020088.
- Gordin D, et al. Comparison of incidence patterns and risk profiles of ST-elevation and non-ST-elevation myocardial infarction in type 1 diabetes in Finland: a nationwide cohort study. Lancet Diabetes Endocrinol. 2026. PMID: 41871591.